270 related articles for article (PubMed ID: 26315862)
1. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
2. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.
Pawlak D; Rangger C; Kolenc Peitl P; Garnuszek P; Maurin M; Ihli L; Kroselj M; Maina T; Maecke H; Erba P; Kremser L; Hubalewska-Dydejczyk A; Mikołajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Mar; 85():1-9. PubMed ID: 26826279
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM).
Wunderlich G; Schiller E; Bergmann R; Pietzsch HJ
Nucl Med Biol; 2010 Nov; 37(8):861-7. PubMed ID: 21055615
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
6. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301
[TBL] [Abstract][Full Text] [Related]
7. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.
Ocak M; Helbok A; von Guggenberg E; Ozsoy Y; Kabasakal L; Kremser L; Decristoforo C
Nucl Med Biol; 2011 Feb; 38(2):171-9. PubMed ID: 21315272
[TBL] [Abstract][Full Text] [Related]
8. Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.
Lipiński PFJ; Garnuszek P; Maurin M; Stoll R; Metzler-Nolte N; Wodyński A; Dobrowolski JC; Dudek MK; Orzełowska M; Mikołajczak R
EJNMMI Res; 2018 Apr; 8(1):33. PubMed ID: 29663167
[TBL] [Abstract][Full Text] [Related]
9. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
10. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
[TBL] [Abstract][Full Text] [Related]
12. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions.
Asti M; Tegoni M; Farioli D; Iori M; Guidotti C; Cutler CS; Mayer P; Versari A; Salvo D
Nucl Med Biol; 2012 May; 39(4):509-17. PubMed ID: 22172388
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes.
Sosabowski JK; Mather SJ
Nat Protoc; 2006; 1(2):972-6. PubMed ID: 17406332
[TBL] [Abstract][Full Text] [Related]
14. (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy.
Liu S; Cheung E; Ziegler MC; Rajopadhye M; Edwards DS
Bioconjug Chem; 2001; 12(4):559-68. PubMed ID: 11459461
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
16. Oxidant and Antioxidant Effects of Gentisic Acid in a
Trindade V; Balter H
Curr Radiopharm; 2020; 13(2):107-119. PubMed ID: 31526356
[TBL] [Abstract][Full Text] [Related]
17. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
18. Influence of different chelators on the radiochemical properties of a 68-Gallium labelled bombesin analogue.
Asti M; Iori M; Capponi PC; Atti G; Rubagotti S; Martin R; Brennauer A; Müller M; Bergmann R; Erba PA; Versari A
Nucl Med Biol; 2014 Jan; 41(1):24-35. PubMed ID: 24183610
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.
Maina T; Konijnenberg MW; KolencPeitl P; Garnuszek P; Nock BA; Kaloudi A; Kroselj M; Zaletel K; Maecke H; Mansi R; Erba P; von Guggenberg E; Hubalewska-Dydejczyk A; Mikolajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Aug; 91():236-42. PubMed ID: 27185299
[TBL] [Abstract][Full Text] [Related]
20. Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with (44m/44)Sc and experimental evidence of the feasibility of an in vivo PET generator.
Huclier-Markai S; Kerdjoudj R; Alliot C; Bonraisin AC; Michel N; Haddad F; Barbet J
Nucl Med Biol; 2014 May; 41 Suppl():e36-43. PubMed ID: 24361353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
